Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.99% $0.757
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 86.33 mill |
EPS: | -1.830 |
P/E: | -0.410 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 114.06 mill |
Avg Daily Volume: | 0.904 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.410 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -0.410 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.602 (-20.40%) $-0.154 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 0.713 - 0.801 ( +/- 5.81%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Miller Edward | Sell | 368 | Common Stock |
2024-04-02 | Brainard Diana | Sell | 1 533 | Common Stock |
2024-04-02 | Hagen Brett R | Sell | 281 | Common Stock |
2024-04-02 | Sinha Vikas | Sell | 885 | Common Stock |
2024-02-20 | Brainard Diana | Sell | 3 097 | Common Stock |
INSIDER POWER |
---|
83.34 |
Last 98 transactions |
Buy: 5 809 216 | Sell: 487 374 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.757 (2.99% ) |
Volume | 0.568 mill |
Avg. Vol. | 0.904 mill |
% of Avg. Vol | 62.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $0.673 | N/A | Active |
---|
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.